Patents Assigned to Allelix Biopharmaceuticals Inc.
  • Patent number: 5290920
    Abstract: Human epidermal growth factor is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such ultrapure human epidermal growth factor includes fractionation of a human epidermal growth factor preparation by reversed phase high performance liquid chromatography in the presence of a cationic ion-pairing agent.
    Type: Grant
    Filed: April 16, 1992
    Date of Patent: March 1, 1994
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Dennis R. Sindrey, Chandra M. Dwivedi
  • Patent number: 5277917
    Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: January 11, 1994
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Yan Xu, Anne E. Goodbody
  • Patent number: 5218093
    Abstract: Biologically active variants of epidermal growth factor are provided, comprising tandemly linked units of monomeric EGF. The variants are useful per se as therapeutic agents to promote wound healing. Production of the multimeric EGF by genetically engineered microbial hosts is also described.
    Type: Grant
    Filed: March 1, 1989
    Date of Patent: June 8, 1993
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Zimin Guo, A. Michael Sills, Nigel A. Skipper
  • Patent number: 5208041
    Abstract: Human parathyroid hormone is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such ultrapure human parathyroid hormone is also described.
    Type: Grant
    Filed: May 23, 1991
    Date of Patent: May 4, 1993
    Assignees: Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
    Inventor: Dennis R. Sindrey
  • Patent number: 5171672
    Abstract: The invention relates to constitutive promoters useful to control gene expression in Aspergillus hosts. The promoters are derived from the Aspergillus nidulans aldA gene.
    Type: Grant
    Filed: August 31, 1989
    Date of Patent: December 15, 1992
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Medhavinee Devchand, David I. Gwynne
  • Patent number: 5169837
    Abstract: Described is a purified osteogenic factor that when delivered to bone in association with a physiologically acceptable delivery vehicle is capable of inducing new bone growth at the bone surface. The osteogenic factor is water soluble, and is characterized physically by a molecular weight of about 2.5 kD when measured by gel filtration under dissociating conditions and an isoelectric point in the pH range from about 4.6 to 7.2. Use of the purified factor in treating bone defects is described. Also described is a method for obtaining the purified factor from mammalian bone.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: December 8, 1992
    Assignees: Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
    Inventors: Alain E. Lagarde, Abdulwahid Abdulwajid, Donna Bueschkens, Deanna Byrne
  • Patent number: 5086039
    Abstract: Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG).
    Type: Grant
    Filed: March 4, 1991
    Date of Patent: February 4, 1992
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventor: Geoffrey L. Hammond
  • Patent number: 4997814
    Abstract: Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG).
    Type: Grant
    Filed: June 9, 1988
    Date of Patent: March 5, 1991
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventor: Geoffrey L. Hammond
  • Patent number: 4973478
    Abstract: Interferon .beta..sub.2 has been identified as the major factor responsible for stimulating hepatocytes to produce anti-inflammatory agents. A method for its use in so stimulating hepatocytes is described herein.
    Type: Grant
    Filed: July 20, 1987
    Date of Patent: November 27, 1990
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Jack Gauldie, Richards, Carl, Peter M. Lansdorp
  • Patent number: 4918011
    Abstract: 3',4'-anhydrovinblastine, a precursor of the anti-tumor alkaloids vincristine and vinblastine, is prepared by the enzymatic coupling of catharanthine and vindoline using an iron-containing compound such as peroxidase optionally in the presence of a peroxide. Substantially enhanced yields are obtained.
    Type: Grant
    Filed: August 4, 1986
    Date of Patent: April 17, 1990
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Anne E. Goodbody, Endo Tsuyoshi, John Vukovic, Masanaru Misawa